
Jacques Robert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9278782/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	γδT, NKT, and MAIT Cells During Evolution: Redundancy or Specialized Functions?. Journal of Immunology, 2022, 209, 217-225.	0.8	14
2	Developing Tadpole Xenopus laevis as a Comparative Animal Model to Study Mycobacterium abscessus Pathogenicity. International Journal of Molecular Sciences, 2021, 22, 806.	4.1	6
3	Exposure to a mixture of 23 chemicals associated with unconventional oil and gas operations alters immune response to challenge in adult mice. Journal of Immunotoxicology, 2021, 18, 105-117.	1.7	1
4	Emerging Pathogens and a Currentâ€Use Pesticide: Potential Impacts on Eastern Hellbenders. Journal of Aquatic Animal Health, 2021, 33, 24-32.	1.4	7
5	Thyroid Disrupting Chemicals in Mixture Perturb Thymocyte Differentiation in <i>Xenopus laevis</i> Tadpoles. Toxicological Sciences, 2021, 181, 262-272.	3.1	8
6	TLR5-Mediated Reactivation of Quiescent Ranavirus FV3 in <i>Xenopus</i> Peritoneal Macrophages. Journal of Virology, 2021, 95, .	3.4	10
7	Targeted Transcriptomics of Frog Virus 3 in Infected Frog Tissues Reveal Non-Coding Regulatory Elements and microRNAs in the Ranaviral Genome and Their Potential Interaction with Host Immune Response. Frontiers in Immunology, 2021, 12, 705253.	4.8	5
8	Virus-Targeted Transcriptomic Analyses Implicate Ranaviral Interaction with Host Interferon Response in Frog Virus 3-Infected Frog Tissues. Viruses, 2021, 13, 1325.	3.3	1
9	The Immune System and the Antiviral Responses in Chinese Giant Salamander, Andrias davidianus. Frontiers in Immunology, 2021, 12, 718627.	4.8	12
10	Immunological Aspects of Chytridiomycosis. Journal of Fungi (Basel, Switzerland), 2020, 6, 234.	3.5	20
11	Cytochrome P450 1B1 polymorphism drives cancer cell stemness and patient outcome in head-and-neck carcinoma. British Journal of Cancer, 2020, 123, 772-784.	6.4	10
12	Developmental exposure to a mixture of unconventional oil and gas chemicals: A review of experimental effects on adult health, behavior, and disease. Molecular and Cellular Endocrinology, 2020, 513, 110722.	3.2	14
13	Broadening and Strengthening Underrepresented Group Inclusion in Immunological Research. Frontiers in Immunology, 2020, 11, 465.	4.8	0
14	Experimental Platform Using the Amphibian Xenopus laevis for Research in Fundamental and Medical Immunology. Cold Spring Harbor Protocols, 2020, 2020, pdb.top106625.	0.3	5
15	Conservation decisions under pressure: Lessons from an exercise in rapid response to wildlife disease. Conservation Science and Practice, 2020, 2, e141.	2.0	11
16	The myeloid lineage is required for the emergence of a regeneration permissive environment following <i>Xenopus</i> tail amputation. Development (Cambridge), 2020, 147, .	2.5	24
17	Characterization and expression of macrophage migration inhibitory factor (mif) in Chinese sturgeon (Acipenser sinensis). Fish and Shellfish Immunology, 2020, 103, 9-16.	3.6	3
18	Sublethal effects of wild-type and a vIF-2α-knockout <i>Frog virus 3</i> on postmetamorphic wood frogs (<i>Rana sylvatica</i>): potential for a stage-specific reservoir. Facets, 2020, 5, 738-757.	2.4	3

#	Article	IF	CITATIONS
19	Adoptive Transfer of Fluorescently Labeled Immune Cells in <i>Xenopus</i> . Cold Spring Harbor Protocols, 2019, 2019, pdb.prot097592.	0.3	2
20	Xenopus Resources: Transgenic, Inbred and Mutant Animals, Training Opportunities, and Web-Based Support. Frontiers in Physiology, 2019, 10, 387.	2.8	44
21	Introduction. Immunological Investigations, 2019, 48, 680-681.	2.0	1
22	Evolutionary Underpinnings of Innate-Like T Cell Interactions with Cancer. Immunological Investigations, 2019, 48, 737-758.	2.0	6
23	Impacts of the MHC class I-like XNC10 and innate-like T cells on tumor tolerance and rejection in the amphibian Xenopus. Carcinogenesis, 2019, 40, 924-935.	2.8	3
24	Critical Role of an MHC Class I-Like/Innate-Like T Cell Immune Surveillance System in Host Defense against Ranavirus (Frog Virus 3) Infection. Viruses, 2019, 11, 330.	3.3	11
25	Developmental exposure to chemicals associated with unconventional oil and gas extraction alters immune homeostasis and viral immunity of the amphibian Xenopus. Science of the Total Environment, 2019, 671, 644-654.	8.0	15
26	Distinct Host–Mycobacterial Pathogen Interactions between Resistant Adult and Tolerant Tadpole Life Stages of Xenopus laevis. Journal of Immunology, 2019, 203, 2679-2688.	0.8	13
27	Isl1 Regulation of Nkx2.1 in the Early Foregut Epithelium Is Required for Trachea-Esophageal Separation and Lung Lobation. Developmental Cell, 2019, 51, 675-683.e4.	7.0	42
28	A Xenopus tadpole alternative model to study innate-like T cell-mediated anti-mycobacterial immunity. Developmental and Comparative Immunology, 2019, 92, 253-259.	2.3	9
29	Lymphocyte Deficiency Induced by Sublethal Irradiation in Xenopus. Cold Spring Harbor Protocols, 2019, 2019, pdb.prot097626.	0.3	3
30	Assessing Antibody Responses to Pathogens or Model Antigens in <i>Xenopus</i> by Enzyme-Linked Immunosorbent Assay (ELISA). Cold Spring Harbor Protocols, 2019, 2019, pdb.prot099234.	0.3	1
31	Distinct MHC class I-like interacting invariant T cell lineage at the forefront of mycobacterial immunity uncovered in Xenopus. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4023-E4031.	7.1	17
32	RNAi-Mediated Loss of Function of <i>Xenopus</i> Immune Genes by Transgenesis. Cold Spring Harbor Protocols, 2018, 2018, pdb.prot101519.	0.3	2
33	Developmental Exposure to a Mixture of 23 Chemicals Associated With Unconventional Oil and Gas Operations Alters the Immune System of Mice. Toxicological Sciences, 2018, 163, 639-654.	3.1	12
34	Frog's DCs have it all in one. European Journal of Immunology, 2018, 48, 415-418.	2.9	1
35	Review of the Amphibian Immune Response to Chytridiomycosis, and Future Directions. Frontiers in Immunology, 2018, 9, 2536.	4.8	98
36	Evaluating Blood Cell Populations in Xenopus Using Flow Cytometry and Differential Counts by Cytospin. Methods in Molecular Biology, 2018, 1865, 265-273.	0.9	1

#	Article	IF	CITATIONS
37	Rag1 and rag2 gene expressions identify lymphopoietic tissues in juvenile and adult Chinese giant salamander (Andrias davidianus). Developmental and Comparative Immunology, 2018, 87, 24-35.	2.3	8
38	Water Contaminants Associated With Unconventional Oil and Gas Extraction Cause Immunotoxicity to Amphibian Tadpoles. Toxicological Sciences, 2018, 166, 39-50.	3.1	21
39	An Ancestral Immune Surveillance System in theÂAmphibian Xenopus Connecting Certain Heat Shock Proteins with Classical and Nonclassical MHC Class I Molecules. , 2018, , 141-155.		0
40	Long term effects of carbaryl exposure on antiviral immune responses in Xenopus laevis. Chemosphere, 2017, 170, 169-175.	8.2	21
41	Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. European Journal of Cancer, 2017, 76, 68-75.	2.8	65
42	Clinical impact of extensive molecular profiling in advanced cancer patients. Journal of Hematology and Oncology, 2017, 10, 45.	17.0	17
43	Evolutionary Aspects of Macrophages Polarization. Results and Problems in Cell Differentiation, 2017, 62, 3-22.	0.7	72
44	Tumor Immunology Viewed from Alternative Animal Models—the Xenopus Story. Current Pathobiology Reports, 2017, 5, 49-56.	3.4	10
45	Collagen-Embedded Tumor Transplantations in <i>Xenopus laevis</i> Tadpoles. Cold Spring Harbor Protocols, 2017, 2017, pdb.prot097584.	0.3	1
46	First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours. European Journal of Cancer, 2017, 86, 240-247.	2.8	14
47	Xenopus-FV3 host-pathogen interactions and immune evasion. Virology, 2017, 511, 309-319.	2.4	22
48	Exploring the functions of nonclassical MHC class Ib genes in Xenopus laevis by the CRISPR/Cas9 system. Developmental Biology, 2017, 426, 261-269.	2.0	22
49	Evolutionary Perspective of Tumorigenesis and Antitumor Immunity: A Comparative Approach. , 2017, , 119-135.		1
50	Humoral Immune Response of Amphibians. , 2017, , .		2
51	Cytotoxic effect of chlorpyrifos ethyl and its degradation derivatives by Pseudomonas peli strain isolated from the Oued Hamdoun River (Tunisia). Toxicology and Industrial Health, 2016, 32, 707-713.	1.4	6
52	Recombinant Ranaviruses for Studying Evolution of Host–Pathogen Interactions in Ectothermic Vertebrates. Viruses, 2016, 8, 187.	3.3	19
53	The Immune System of Amphibians. , 2016, , 486-492.		4
54	Evolution of innate-like T cells and their selection by MHC class I-like molecules. Immunogenetics, 2016, 68, 525-536.	2.4	32

#	Article	IF	CITATIONS
55	Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR112 and NR113 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients. Clinical Pharmacokinetics, 2016, 55, 1145-1157.	3.5	22
56	Frog Virus 3 dissemination in the brain of tadpoles, but not in adult Xenopus, involves blood brain barrier dysfunction. Scientific Reports, 2016, 6, 22508.	3.3	19
57	Genome evolution in the allotetraploid frog Xenopus laevis. Nature, 2016, 538, 336-343.	27.8	849
58	Efficacy of doxorubicin-transferrin conjugate in apoptosis induction in human leukemia cells through reactive oxygen species generation. Cellular Oncology (Dordrecht), 2016, 39, 107-118.	4.4	20
59	Ouro proteins are not essential to tail regression during <i>Xenopus tropicalis</i> metamorphosis. Genes To Cells, 2016, 21, 275-286.	1.2	15
60	Preface to the special issue "Hematopoiesis and immunity― Developmental and Comparative Immunology, 2016, 58, A1.	2.3	0
61	Amphibian macrophage development and antiviral defenses. Developmental and Comparative Immunology, 2016, 58, 60-67.	2.3	36
62	Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy. Cancer Chemotherapy and Pharmacology, 2016, 77, 5-18.	2.3	63
63	A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy. Annals of Oncology, 2016, 27, 199-200.	1.2	12
64	Distinct functional roles of amphibian (<i>Xenopus laevis</i>) colony-stimulating factor-1- and interleukin-34-derived macrophages. Journal of Leukocyte Biology, 2015, 98, 641-649.	3.3	42
65	Prominent Amphibian (Xenopus laevis) Tadpole Type III Interferon Response to the Frog Virus 3 Ranavirus. Journal of Virology, 2015, 89, 5072-5082.	3.4	49
66	Xenopus: An in vivo model for imaging the inflammatory response following injury and bacterial infection. Developmental Biology, 2015, 408, 213-228.	2.0	40
67	Retention of duplicated ITAM-containing transmembrane signaling subunits in the tetraploid amphibian species Xenopus laevis. Developmental and Comparative Immunology, 2015, 53, 158-168.	2.3	0
68	Polymorphisms inSLCO1B3andNR112as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination. Pharmacogenomics, 2015, 16, 1439-1450.	1.3	14
69	Nonclassical MHC-Restricted Invariant Vα6 T Cells Are Critical for Efficient Early Innate Antiviral Immunity in the Amphibian <i>Xenopus laevis</i> . Journal of Immunology, 2015, 195, 576-586.	0.8	24
70	Characterization of Frog Virus 3 knockout mutants lacking putative virulence genes. Virology, 2015, 485, 162-170.	2.4	26
71	Semi-solid tumor model in Xenopus laevis/gilli cloned tadpoles for intravital study of neovascularization, immune cells and melanophore infiltration. Developmental Biology, 2015, 408, 205-212.	2.0	13
72	Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial. Pharmacogenomics Journal, 2015, 15, 63-68.	2.0	10

#	Article	IF	CITATIONS
73	Ranavirus Host Immunity and Immune Evasion. , 2015, , 141-170.		19
74	Inflammation-Induced Reactivation of the Ranavirus Frog Virus 3 in Asymptomatic Xenopus laevis. PLoS ONE, 2014, 9, e112904.	2.5	28
75	Environmental dependency of amphibian–ranavirus genotypic interactions: evolutionary perspectives on infectious diseases. Evolutionary Applications, 2014, 7, 723-733.	3.1	50
76	The Amphibian (Xenopus laevis) Type I Interferon Response to Frog Virus 3: New Insight into Ranavirus Pathogenicity. Journal of Virology, 2014, 88, 5766-5777.	3.4	73
77	Divergent antiviral roles of amphibian (<i>Xenopus laevis</i>) macrophages elicited by colony-stimulating factor-1 and interleukin-34. Journal of Leukocyte Biology, 2014, 96, 1143-1153.	3.3	46
78	Identification of methylguanine methyltransferase polymorphisms as genetic markers of individual susceptibility to therapy-related myeloid neoplasms. European Journal of Cancer, 2014, 50, 418-424.	2.8	8
79	A critical role of non-classical MHC in tumor immune evasion in the amphibian Xenopus model. Carcinogenesis, 2014, 35, 1807-1813.	2.8	24
80	A functionalized heterobimetallic ^{99m} Tc/Re complex as a potential dual-modality imaging probe: synthesis, photophysical properties, cytotoxicity and cellular imaging investigations. Dalton Transactions, 2014, 43, 439-450.	3.3	25
81	Evolution of nonclassical MHC-dependent invariant T cells. Cellular and Molecular Life Sciences, 2014, 71, 4763-4780.	5.4	16
82	Negative effects of low dose atrazine exposure on the development of effective immunity to FV3 in Xenopus laevis. Developmental and Comparative Immunology, 2014, 47, 52-58.	2.3	32
83	Induction of apoptosis by doxorubicin–transferrin conjugate compared to free doxorubicin in the human leukemia cell lines. Chemico-Biological Interactions, 2014, 220, 140-148.	4.0	20
84	On the use of pharmacogenetics in cancer treatment and clinical trials. European Journal of Cancer, 2014, 50, 2532-2543.	2.8	21
85	Unusual evolutionary conservation and further species-specific adaptations of a large family of nonclassical MHC class Ib genes across different degrees of genome ploidy in the amphibian subfamily Xenopodinae. Immunogenetics, 2014, 66, 411-426.	2.4	23
86	A prominent role for invariant T cells in the amphibian Xenopus laevis tadpoles. Immunogenetics, 2014, 66, 513-523.	2.4	24
87	No association between XRCC3 Thr241Met and XPD Lys751Gln polymorphisms and the risk of colorectal cancer in West Algerian population: a case–control study. Medical Oncology, 2014, 31, 942.	2.5	12
88	FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC Research Notes, 2014, 7, 260.	1.4	15
89	Differential transcription of fathead minnow immune-related genes following infection with frog virus 3, an emerging pathogen of ectothermic vertebrates. Virology, 2014, 456-457, 77-86.	2.4	20
90	Transferrin as a drug carrier: Cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells. Toxicology in Vitro, 2014, 28, 187-197.	2.4	35

#	Article	IF	CITATIONS
91	Antitumor activity of semisynthetic derivatives of Aconitum alkaloids. Investigational New Drugs, 2014, 32, 60-67.	2.6	5
92	Mechanisms of amphibian macrophage development: characterization of the Xenopus laevis colony-stimulating factor-1 receptor. International Journal of Developmental Biology, 2014, 58, 757-766.	0.6	12
93	Antioxidant, Anti-inflammatory and Antiproliferative Effects of Aqueous Extracts of Three Mediterranean Brown Seaweeds of the Genus Cystoseira. Iranian Journal of Pharmaceutical Research, 2014, 13, 207-20.	0.5	44
94	Decolorization does not always mean detoxification: case study of a newly isolated Pseudomonas peli for decolorization of textile wastewater. Environmental Science and Pollution Research, 2013, 20, 5790-5796.	5.3	16
95	Nonclassical MHC class I-dependent invariant T cells are evolutionarily conserved and prominent from early development in amphibians. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14342-14347.	7.1	60
96	Antiproliferative activity and phenolics of the Mediterranean seaweed Laurencia obusta. Industrial Crops and Products, 2013, 47, 252-255.	5.2	25
97	R4 regulators of G protein signaling (RGS) identify an ancient MHC-linked synteny group. Immunogenetics, 2013, 65, 145-156.	2.4	8
98	Evaluation of antiproliferative and antioxidant activities of the organic extract and its polar fractions from the Mediterranean gorgonian Eunicella singularis. Environmental Toxicology and Pharmacology, 2013, 36, 339-346.	4.0	13
99	Aconitum Alkaloids and Biological Activities. , 2013, , 1503-1523.		8
100	Effective RNAi-mediated β2-microglobulin loss of function by transgenesis in <i>Xenopus laevis</i> . Biology Open, 2013, 2, 335-342.	1.2	15
101	Pharmacogénétique et pharmacogénomie. , 2013, , 59-74.		1
102	Colony-Stimulating Factor-1-Responsive Macrophage Precursors Reside in the Amphibian <i>(Xenopus laevis)</i> Bone Marrow rather than the Hematopoietic Subcapsular Liver. Journal of Innate Immunity, 2013, 5, 531-542.	3.8	43
103	Recent Research Progress and Potential Uses of the Amphibian Xenopus as a Biomedical and Immunological Model System. Resources, 2013, 2, 167-183.	3.5	3
104	Hsp72 mediates stronger antigen-dependent non-classical MHC class Ib anti-tumor responses than hsc73 in Xenopus laevis. Cancer Immunity, 2013, 13, 4.	3.2	5
105	Immune Evasion Strategies of Ranaviruses and Innate Immune Responses to These Emerging Pathogens. Viruses, 2012, 4, 1075-1092.	3.3	55
106	Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity. Carcinogenesis, 2012, 33, 962-968.	2.8	13
107	Ranavirus: past, present and future. Biology Letters, 2012, 8, 481-483.	2.3	80
108	Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients. Pharmacogenomics, 2012, 13, 497-504.	1.3	2

#	Article	IF	CITATIONS
109	Gene Expression Signature Predicting High-Grade Prostate Cancer Responses to Oxaliplatin. Molecular Pharmacology, 2012, 82, 1205-1216.	2.3	4
110	Susceptibility of Xenopus laevis tadpoles to infection by the ranavirus Frog-Virus 3 correlates with a reduced and delayed innate immune response in comparison with adult frogs. Virology, 2012, 432, 435-443.	2.4	77
111	"Ranaviruses: An emerging threat to ectothermic vertebrates―Report of the First International Symposium on Ranaviruses, Minneapolis MN July 8, 2011. Developmental and Comparative Immunology, 2012, 36, 259-261.	2.3	13
112	Evaluation of antiproliferative and anti-inflammatory activities of methanol extract and its fractions from the Mediterranean sponge. Cancer Cell International, 2012, 12, 18.	4.1	13
113	Hemisynthesis and antiproliferative properties of mono-[O-(14-benzoylaconine-8-yl)]esters and bis-[O-(14-benzoylaconine-8-yl)]esters. European Journal of Medicinal Chemistry, 2012, 54, 343-351.	5.5	9
114	Short curcumin treatment modulates oxidative stress, arginase activity, aberrant crypt foci, and TGF-β1 and HES-1 transcripts in 1,2-dimethylhydrazine-colon carcinogenesis in mice. Toxicology, 2012, 302, 308-317.	4.2	24
115	Antiâ€Inflammatory and Antiproliferative Activities of Organic Fractions from the Mediterranean Brown Seaweed, <i><scp>C</scp>ystoseira Compressa</i> . Drug Development Research, 2012, 73, 82-89.	2.9	17
116	7β-Hydroxycholesterol-induced energy stress leads to sequential opposing signaling responses and to death of c6 glioblastoma cells. Biochemical Pharmacology, 2012, 83, 37-46.	4.4	18
117	Optimized transgenesis in <i>Xenopus laevis/gilli</i> isogenetic clones for immunological studies. Genesis, 2012, 50, 300-306.	1.6	7
118	Abstract 1871: Role of CYP1B1 gene polymorphisms in anticancer drug cytotoxicity as studied on isogenic cell lines. , 2012, , .		2
119	Role of DNA Repair Gene Polymorphisms in the Efficiency of Platinum-Based Adjuvant Chemotherapy for Non-Small Cell Lung Cancer. Molecular Diagnosis and Therapy, 2011, 15, 159-166.	3.8	22
120	Antiviral Immunity in Amphibians. Viruses, 2011, 3, 2065-2086.	3.3	69
121	Phylogenetic and developmental study of CD4, CD8 α and β T cell co-receptor homologs in two amphibian species, Xenopus tropicalis and Xenopus laevis. Developmental and Comparative Immunology, 2011, 35, 366-377.	2.3	27
122	The genus Xenopus as a multispecies model for evolutionary and comparative immunobiology of the 21st century. Developmental and Comparative Immunology, 2011, 35, 916-923.	2.3	39
123	Anti-inflammatory, anti-proliferative and anti-oxidant activities of organic extracts from the Mediterranean seaweed, Cystoseira crinita. African Journal of Biotechnology, 2011, 10, .	0.6	6
124	Waterborne infectivity of the Ranavirus frog virus 3 in Xenopus laevis. Virology, 2011, 417, 410-417.	2.4	54
125	Encapsulation of Docetaxel into PEGylated Gold Nanoparticles for Vectorization to Cancer Cells. ChemMedChem, 2011, 6, 2003-2008.	3.2	37
126	<i>ERCC5</i> / <i>XPG</i> , <i>ERCC1,</i> and <i>BRCA1</i> gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer, 2011, 117, 3445-3456.	4.1	57

#	Article	IF	CITATIONS
127	Improved Knockout Methodology Reveals That Frog Virus 3 Mutants Lacking either the <i>18K</i> Immediate-Early Gene or the Truncated <i>vIF-2</i> α Gene Are Defective for Replication and GrowthIn VivoIournal of Virology, 2011, 85, 11131-11138.	3.4	44
128	<i>ERCC1</i> and <i>ERCC2</i> Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis. Clinical Cancer Research, 2011, 17, 1632-1640.	7.0	138
129	Remarkable Conservation of Distinct Nonclassical MHC Class I Lineages in Divergent Amphibian Species. Journal of Immunology, 2011, 186, 372-381.	0.8	45
130	Comparative in vivo Study of gp96 Adjuvanticity in the Frog Xenopus laevis . Journal of Visualized Experiments, 2010, , .	0.3	9
131	Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mammalian Genome, 2010, 21, 427-441.	2.2	147
132	Emerging Ranaviral Infectious Diseases and Amphibian Decline. Diversity, 2010, 2, 314-330.	1.7	24
133	Innate Immune Responses and Permissiveness to Ranavirus Infection of Peritoneal Leukocytes in the Frog <i>Xenopus laevis</i> . Journal of Virology, 2010, 84, 4912-4922.	3.4	104
134	The Genome of the Western Clawed Frog <i>Xenopus tropicalis</i> . Science, 2010, 328, 633-636.	12.6	708
135	Cytochrome P450 1B1 Gene Polymorphisms as Predictors of Anticancer Drug Activity: Studies with <i>In vitro</i> Models. Molecular Cancer Therapeutics, 2010, 9, 3315-3321.	4.1	18
136	The amphibians Xenopus laevis and Silurana tropicalis possess a family of activating KIR-related Immunoglobulin-like Receptors. Developmental and Comparative Immunology, 2010, 34, 308-315.	2.3	14
137	Phylogeny, genomic organization and expression of λ and κ immunoglobulin light chain genes in a reptile, Anolis carolinensis. Developmental and Comparative Immunology, 2010, 34, 579-589.	2.3	43
138	Comparative study of tumorigenesis and tumor immunity in invertebrates and nonmammalian vertebrates. Developmental and Comparative Immunology, 2010, 34, 915-925.	2.3	70
139	Tumorigenesis and anti-tumor immune responses in Xenopus. Frontiers in Bioscience - Landmark, 2009, Volume, 167.	3.0	35
140	Expression Profiling the Temperature-Dependent Amphibian Response to Infection by Batrachochytrium dendrobatidis. PLoS ONE, 2009, 4, e8408.	2.5	135
141	Comparative and developmental study of the immune system in <i>Xenopus</i> . Developmental Dynamics, 2009, 238, 1249-1270.	1.8	237
142	Isolation of a Latimeria menadoensis heat shock protein 70 (Lmhsp70) that has all the features of an inducible gene and encodes a functional molecular chaperone. Molecular Genetics and Genomics, 2009, 282, 185-196.	2.1	6
143	Xenopus, a unique comparative model to explore the role of certain heat shock proteins and non-classical MHC class Ib gene products in immune surveillance. Immunologic Research, 2009, 45, 114-122.	2.9	11
144	The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models. British Journal of Cancer, 2009, 101, 350-356.	6.4	14

#	Article	IF	CITATIONS
145	Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model. European Journal of Cancer, 2009, 45, 2391-2401.	2.8	16
146	Control of asthma in children: still unacceptable? A French cross-sectional study. Respiratory Medicine, 2009, 103, 1383-1391.	2.9	48
147	Novel nonclassical MHC class Ib genes associated with CD8 T cell development and thymic tumors. Molecular Immunology, 2009, 46, 1775-1786.	2.2	28
148	Diversity of the FcR- and KIR-related genes in an amphibian Xenopus. Frontiers in Bioscience - Landmark, 2009, Volume, 130.	3.0	13
149	Mass mortality associated with a frog virus 3- like Ranavirus infection in farmed tadpoles Rana catesbeiana from Brazil. Diseases of Aquatic Organisms, 2009, 86, 181-191.	1.0	54
150	Platinum Drugs and DNA Repair: Lessons from the NCI Panel and Clinical Correlates. , 2009, , 149-155.		1
151	Genome-Wide Transcriptional Response of Silurana (Xenopus) tropicalis to Infection with the Deadly Chytrid Fungus. PLoS ONE, 2009, 4, e6494.	2.5	84
152	Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene. Cancer Chemotherapy and Pharmacology, 2008, 61, 481-488.	2.3	24
153	Synthesis and antiproliferative activity of aryl- and heteroaryl-hydrazones derived from xanthone carbaldehydes. European Journal of Medicinal Chemistry, 2008, 43, 1336-1343.	5.5	59
154	In vivo and in vitro techniques for comparative study of antiviral T-cell responses in the amphibian Xenopus. Biological Procedures Online, 2008, 10, 1-8.	2.9	9
155	Role of Daunorubicinol in Daunorubicin-Induced Cardiotoxicity as Evaluated with the Model of Isolated Perfused Rat Heart. Basic and Clinical Pharmacology and Toxicology, 2008, 88, 250-254.	0.0	1
156	Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. British Journal of Cancer, 2008, 99, 1239-1245.	6.4	52
157	The Xenopus FcR family demonstrates continually high diversification of paired receptors in vertebrate evolution. BMC Evolutionary Biology, 2008, 8, 148.	3.2	36
158	Protein arginine (<i>N</i>)â€methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins. FEBS Letters, 2008, 582, 1483-1489.	2.8	49
159	Impact of EGFR Gene Polymorphisms on Anticancer Drug Cytotoxicity In Vitro. Molecular Diagnosis and Therapy, 2008, 12, 225-234.	3.8	16
160	Phylogenetic Conservation of Glycoprotein 96 Ability to Interact with CD91 and Facilitate Antigen Cross-Presentation. Journal of Immunology, 2008, 180, 3176-3182.	0.8	37
161	A chemotherapy-associated senescence bystander effect in breast cancer cells. Cancer Biology and Therapy, 2008, 7, 864-872.	3.4	55
162	Inhibition of Topoisomerase I Cleavage Activity by Thiol-reactive Compounds. Journal of Biological Chemistry, 2007, 282, 14403-14412.	3.4	22

#	Article	IF	CITATIONS
163	Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity. Oncology Reports, 2007, 17, 1213.	2.6	4
164	Localization and Differential Expression of Activation-Induced Cytidine Deaminase in the Amphibian <i>Xenopus</i> upon Antigen Stimulation and during Early Development. Journal of Immunology, 2007, 179, 6783-6789.	0.8	65
165	Characterization of Primary and Memory CD8 T-Cell Responses against Ranavirus (FV3) in Xenopus laevis. Journal of Virology, 2007, 81, 2240-2248.	3.4	73
166	In Vivo Study of T-Cell Responses to Skin Alloantigens in Xenopus Using a Novel Whole-Mount Immunohistology Method. Transplantation, 2007, 83, 159-166.	1.0	12
167	XENOPUS LAEVIS: A POSSIBLE VECTOR OF RANAVIRUS INFECTION?. Journal of Wildlife Diseases, 2007, 43, 645-652.	0.8	83
168	A phase II study for the evaluation of quinine as a modulator of multidrug resistance in non-Hodgkin's lymphoma. European Journal of Cancer, 2007, 43, 53-54.	2.8	4
169	Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel. European Journal of Cancer, 2007, 43, 955-962.	2.8	33
170	Determination ofERCC2Lys751Gln andGSTP1Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics, 2007, 8, 1693-1703.	1.3	60
171	Conservation of ILâ€6 transâ€signaling mechanisms controlling Lâ€selectin adhesion by feverâ€range thermal stress. European Journal of Immunology, 2007, 37, 2856-2867.	2.9	30
172	Involvement of nonclassical MHC class Ib molecules in heat shock protein-mediated anti-tumor responses. European Journal of Immunology, 2007, 37, 1494-1501.	2.9	25
173	Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: Predictiveness and pitfalls. Cell Biology and Toxicology, 2007, 23, 27-37.	5.3	54
174	Long-term and short-term models for studying anthracycline cardiotoxicity and protectors. Cardiovascular Toxicology, 2007, 7, 135-139.	2.7	35
175	Experimental study of dexrazoxane–anthracycline combinations using the model of isolated perfused rat heart. Toxicology Letters, 2006, 161, 37-42.	0.8	13
176	Structural Phylogenetic Analysis of Activation-Induced Deaminase Function. Journal of Immunology, 2006, 177, 355-361.	0.8	34
177	Generation of a long-lasting, protective, and neutralizing antibody response to the ranavirus FV3 by the frog Xenopus. Developmental and Comparative Immunology, 2006, 30, 649-657.	2.3	61
178	Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. Biochemical Pharmacology, 2006, 71, 1162-1174.	4.4	68
179	Genetic polymorphisms of the XPG and XPD nucleotide excision repair genes in sarcoma patients. International Journal of Cancer, 2006, 119, 1732-1735.	5.1	18
180	Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-Ã-vis the NCI-60 panel. Pharmacogenomics, 2006, 7, 843-852.	1.3	37

#	Article	IF	CITATIONS
181	A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. British Journal of Cancer, 2006, 95, 571-580.	6.4	53
182	Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines. British Journal of Cancer, 2006, 95, 906-913.	6.4	19
183	Major improvement of the reference method of the French drug resistance network for P-glycoprotein detection in human haematological malignancies. Leukemia Research, 2005, 29, 1029-1037.	0.8	3
184	8-O-Azeloyl-14-benzoylaconine: A new alkaloid from the roots of Aconitum karacolicum Rapcs and its antiproliferative activities. Bioorganic and Medicinal Chemistry, 2005, 13, 6493-6501.	3.0	34
185	Adaptive immunity and histopathology in frog virus 3-infected Xenopus. Virology, 2005, 332, 667-675.	2.4	78
186	CD91 up-regulates upon immune stimulation in Xenopus adult but not larval peritoneal leukocytes. Immunogenetics, 2005, 56, 735-742.	2.4	12
187	Predicting drug response and toxicity based on gene polymorphisms. Critical Reviews in Oncology/Hematology, 2005, 54, 171-196.	4.4	96
188	Pharmacogï;1⁄2nï;1⁄2tique?pharmacogï;1⁄2nomie, quelle est la diffï;1⁄2rence?. Oncologie, 2005, 7, 4-5.	0.7	0
189	Immunotoxicology of amphibians. Applied Herpetology, 2005, 2, 297-309.	0.5	10
190	Pharmacogenetics and Pharmacogenomics as New Tools to Optimise Cancer Chemotherapy. Journal of Chemotherapy, 2004, 16, 22-24.	1.5	5
191	Molecular Determinants of the Cytotoxicity of Platinum Compounds. Cancer Research, 2004, 64, 356-362.	0.9	87
192	Anti-tumor MHC class Ia-unrestricted CD8 T cell cytotoxicity elicited by the heat shock protein gp96. European Journal of Immunology, 2004, 34, 2449-2458.	2.9	23
193	Multidrug Resistance Reversal Agents. ChemInform, 2004, 35, no.	0.0	2
194	Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clinical Pharmacology and Therapeutics, 2004, 76, 528-535.	4.7	64
195	Predicting drug response based on gene expression. Critical Reviews in Oncology/Hematology, 2004, 51, 205-227.	4.4	15
196	Xenopus as an experimental model for studying evolution of hsp–immune system interactions. Methods, 2004, 32, 42-53.	3.8	28
197	Phylogenetic Conservation of gp96-Mediated Antigen-Specific Cellular Immunity: New Evidence from Adoptive Cell Transfer in Xenopus. Transplantation, 2004, 78, 1415-1421.	1.0	18
198	Predicting drug response based on gene expression. Critical Reviews in Oncology/Hematology, 2004, 51, 205-227.	4.4	32

#	Article	IF	CITATIONS
199	Development and characterization of a model system to study amphibian immune responses to iridoviruses. Virology, 2003, 311, 254-262.	2.4	139
200	DNA topoisomerase IIα expression and the response to primary chemotherapy in breast cancer. British Journal of Cancer, 2003, 89, 666-671.	6.4	87
201	Multidrug Resistance Reversal Agents. Journal of Medicinal Chemistry, 2003, 46, 4805-4817.	6.4	297
202	Evolution of heat shock protein and immunity. Developmental and Comparative Immunology, 2003, 27, 449-464.	2.3	184
203	Ontogeny of Xenopus NK cells in the absence of MHC class I antigens. Developmental and Comparative Immunology, 2003, 27, 715-726.	2.3	30
204	Signaling FcRÎ ³ and TCRζ subunit homologs in the amphibian Xenopus laevis. Developmental and Comparative Immunology, 2003, 27, 727-733.	2.3	13
205	Bacterial stimulation upregulates the surface expression of the stress protein gp96 on B cells in the frog Xenopus. Cell Stress and Chaperones, 2003, 8, 265.	2.9	15
206	Evolution of the immunomodulatory role of the heat shock protein gp96. Cellular and Molecular Biology, 2003, 49, 263-75.	0.9	6
207	Minor Histocompatibility Antigen-Specific MHC-Restricted CD8 T Cell Responses Elicited by Heat Shock Proteins. Journal of Immunology, 2002, 168, 1697-1703.	0.8	49
208	Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan: Figure 1. Drug Metabolism and Disposition, 2002, 30, 731-733.	3.3	43
209	Alterations in the expression of cytochrome c oxidase subunits in doxorubicin-resistant leukemia K562 cells. Biochemical Pharmacology, 2002, 63, 823-831.	4.4	25
210	Identification and characterization of Xenopus CD8+ T cells expressing an NK cell-associated molecule. European Journal of Immunology, 2002, 32, 1574.	2.9	24
211	Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes. Cancer Chemotherapy and Pharmacology, 2002, 49, 274-280.	2.3	10
212	Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemotherapy and Pharmacology, 2002, 49, 329-335.	2.3	44
213	In vitro thymocyte differentiation in MHC class I-negative Xenopus larvae. Developmental and Comparative Immunology, 2001, 25, 323-336.	2.3	15
214	Resistance to cytotoxic agents. Current Opinion in Pharmacology, 2001, 1, 353-357.	3.5	11
215	Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines. Anti-Cancer Drugs, 2001, 12, 247-258.	1.4	25
216	MHC-RESTRICTED AND -UNRESTRICTED CD8 T CELLS. Transplantation, 2001, 72, 1830-1835.	1.0	31

#	Article	IF	CITATIONS
217	Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia. Cancer Chemotherapy and Pharmacology, 2001, 47, 15-21.	2.3	58
218	Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome. Biomedical Applications, 2001, 757, 257-267.	1.7	34
219	Metabolism of methoxymorpholino-doxorubicin in rat, dog and monkey liver microsomes: comparison with human microsomes. Fundamental and Clinical Pharmacology, 2001, 15, 373-378.	1.9	5
220	Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver. Journal of Pharmaceutical Sciences, 2001, 90, 722-731.	3.3	10
221	Phylogenetic conservation of the molecular and immunological properties of the chaperones gp96 and hsp70. European Journal of Immunology, 2001, 31, 186-195.	2.9	64
222	Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants. British Journal of Cancer, 2001, 85, 1077-1083.	6.4	54
223	Phylogenetic conservation of the molecular and immunological properties of the chaperones gp96 and hsp70. European Journal of Immunology, 2001, 31, 186-195.	2.9	1
224	Immunological Properties of Heat Shock Proteins are Phylogenetically Conserved. Advances in Experimental Medicine and Biology, 2001, 484, 237-249.	1.6	4
225	Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants. British Journal of Cancer, 2001, 85, 1077-1083.	6.4	1
226	New targets, new drugs. Critical Reviews in Oncology/Hematology, 2000, 34, 81-82.	4.4	0
227	B-cell development in the amphibianXenopus. Immunological Reviews, 2000, 175, 201-213.	6.0	97
228	Down-regulation of bcr-abl and bcl-xL expression in a leukemia cell line and its doxorubicin-resistant variant by topoisomerase II inhibitors. Biochemical Pharmacology, 2000, 60, 1823-1828.	4.4	15
229	Preclinical Evaluation of the Cardiotoxicity of Taxane–Anthracycline Combinations Using the Model of Isolated Perfused Rat Heart. Toxicology and Applied Pharmacology, 2000, 163, 135-140.	2.8	22
230	Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. Cancer Chemotherapy and Pharmacology, 2000, 45, 9-14.	2.3	14
231	B-cell development in the amphibian Xenopus. Immunological Reviews, 2000, 175, 201-213.	6.0	7
232	In vitro differentiation of a CD4/CD8 double-positive equivalent thymocyte subset in adult Xenopus. International Immunology, 1999, 11, 499-508.	4.0	21
233	Multidrug resistance in oncology: diagnostic and therapeutic approaches. European Journal of Clinical Investigation, 1999, 29, 536-545.	3.4	60
234	A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients. Leukemia, 1999, 13, 1491-1496.	7.2	21

#	Article	IF	CITATIONS
235	Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin. British Journal of Cancer, 1999, 81, 24-27.	6.4	19
236	Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. Anti-Cancer Drugs, 1999, 10, 671-676.	1.4	49
237	Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage. Journal of Clinical Oncology, 1999, 17, 1105-1105.	1.6	185
238	Cell surface expression of the endoplasmic reticular heat shock protein gp96 is phylogenetically conserved. Journal of Immunology, 1999, 163, 4133-9.	0.8	58
239	Evolution of immune surveillance and tumor immunity: studies in Xenopus. Immunological Reviews, 1998, 166, 231-243.	6.0	60
240	Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: A method validated by the laboratories of the French Drug Resistance Network. , 1998, 34, 248-256.		46
241	Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy. Pathology and Oncology Research, 1998, 4, 171-178.	1.9	19
242	The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 1998, 17, 785-792.	2.8	25
243	Drug resistance to topoisomerase II inhibitors. Biochimie, 1998, 80, 247-254.	2.6	36
244	Ontogeny of CTX expression in xenopus. Developmental and Comparative Immunology, 1998, 22, 605-612.	2.3	19
245	Doxorubicin-Induced Alterations of c-myc and c-jun Gene Expression in Rat Glioblastoma Cells: Role of c-jun in Drug Resistance and Cell Death. Biochemical Pharmacology, 1998, 55, 1963-1971.	4.4	17
246	Approaches to multidrug resistance reversal. Expert Opinion on Investigational Drugs, 1998, 7, 929-939.	4.1	14
247	Determination of unbound platinum after oxaliplatin administration. Anti-Cancer Drugs, 1998, 9, 223-228.	1.4	10
248	Transcriptional down-regulation of c-myc expression in an erythroleukemic cell line, K562, and its doxorubicin-resistant variant by two topoisomerase II inhibitors, doxorubicin and amsacrine. Anti-Cancer Drugs, 1998, 9, 245-254.	1.4	11
249	Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients Journal of Clinical Oncology, 1998, 16, 1470-1478.	1.6	143
250	Resistance to Anticancer Drugs: Are We Ready to Use Biologic Information for the Treatment of Patients With Cancer?. Therapeutic Drug Monitoring, 1998, 20, 581-587.	2.0	3
251	Pharmacology of irinotecan. Drugs of Today, 1998, 34, 777.	1.1	28
252	Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Research, 1998, 58, 468-72.	0.9	103

#	Article	IF	CITATIONS
253	Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. Journal of Pharmacology and Experimental Therapeutics, 1998, 286, 578-83.	2.5	74
254	Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes. Drug Metabolism and Disposition, 1998, 26, 769-74.	3.3	32
255	A Simple Chromatographic Method for the Analysis of Pyrimidines and their Dihydrogenated Metabolites. Journal of Liquid Chromatography and Related Technologies, 1997, 20, 3155-3172.	1.0	33
256	Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin. Anti-Cancer Drugs, 1997, 8, 610-617.	1.4	14
257	Confocal microscopy of idarubicin localisation. British Journal of Cancer, 1997, 76, 136-136.	6.4	1
258	Antibody Cross-Linking of the Thymocyte-Specific Cell Surface Molecule CTX Causes Abnormal Mitosis and Multinucleation of Tumor Cells. Experimental Cell Research, 1997, 235, 227-237.	2.6	10
259	Genealogical study of oculopharyngeal muscular dystrophy in France. Neuromuscular Disorders, 1997, 7, S34-S37.	0.6	11
260	Cross-linking CTX, a novel thymocyte-specific molecule, inhibits the growth of lymphoid tumor cells in xenopus. Molecular Immunology, 1997, 34, 133-143.	2.2	16
261	Clucuronidation of SNâ€38, the Active Metabolite of Irinotecan, by Human Hepatic Microsomes. Basic and Clinical Pharmacology and Toxicology, 1997, 80, 91-96.	0.0	46
262	Multicentric evaluation of the MDR phenotype in leukemia. Leukemia, 1997, 11, 1086-1094.	7.2	87
263	French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours. Leukemia, 1997, 11, 1095-1106.	7.2	38
264	Differential Stabilization of Topoisomerase-II-DNA Cleavable Complexes by Doxorubicin and Etoposide in Doxorubicin-Resistant Rat Glioblastoma Cells. FEBS Journal, 1997, 245, 307-315.	0.2	16
265	The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes Differential hydrolysis for the lactone and carboxylate forms. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 356, 257-262.	3.0	55
266	Inhibition of protein kinase C in multidrug-resistant cells by modulators of multidrug resistance. Journal of Cancer Research and Clinical Oncology, 1997, 123, 201-210.	2.5	15
267	Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma. Biomedical Applications, 1997, 695, 409-416.	1.7	37
268	Effects of thymectomy and tolerance induction on tumor immunity in adultXenopus laevis. , 1997, 70, 330-334.		23
269	Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clinical Cancer Research, 1997, 3, 1261-6.	7.0	87
270	Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. British Journal of Pharmacology, 1996, 117, 1593-1599.	5.4	52

#	Article	IF	CITATIONS
271	Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by Human Liver Carboxylesterase. Biochemical Pharmacology, 1996, 52, 1103-1111.	4.4	221
272	Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation. Cancer Letters, 1996, 109, 203-209.	7.2	12
273	Effects of modulators of multidrug resistance on the expression of the MDR1 gene in human KB cells in culture. Anti-Cancer Drugs, 1996, 7, 738-744.	1.4	21
274	On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Cancer Chemotherapy and Pharmacology, 1996, 37, 556-560.	2.3	35
275	CTX, a novel molecule specifically expressed on the surface of cortical thymocytes inXenopus. European Journal of Immunology, 1996, 26, 780-791.	2.9	64
276	Semisynthesis of RPR 121056A, a major metabolite of irinotecan (CPT-11). Tetrahedron Letters, 1996, 37, 6327-6330.	1.4	8
277	Xenopus lymphoid tumor cell lines. , 1996, , 2367-2377.		1
278	Xenopus lymphoid tumor cell lines. , 1996, , 2367-2377.		6
279	Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Research, 1996, 56, 3689-94.	0.9	85
280	Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line. Anti-Cancer Drugs, 1995, 6, 135-146.	1.4	11
281	Ontogeny of the alloimmune response against a transplanted tumor in Xenopus laevis. Differentiation, 1995, 59, 135-144.	1.9	50
282	Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line. International Journal of Cancer, 1995, 62, 283-290.	5.1	30
283	Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. , 1995, 68, 269-296.		79
284	Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells. European Journal of Cancer, 1995, 31, 389-394.	2.8	28
285	956 Pharmacokinetics and interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. European Journal of Cancer, 1995, 31, S199.	2.8	3
286	A Xenopus lymphoid tumor cell line with complete Ig genes rearrangements and T-cell characteristics. Molecular Immunology, 1995, 32, 583-593.	2.2	17
287	Azelastine and flezelastine as reversing agents of multidrug resistance: Pharmacological and molecular studies. Biochemical Pharmacology, 1995, 50, 169-175.	4.4	19
288	Identification and kinetics of a ?-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemotherapy and Pharmacology, 1995, 36, 176-179.	2.3	121

#	Article	IF	CITATIONS
289	Direct evaluation of intracellular accumulation of free and polymer-bound anthracyclines. Cancer Chemotherapy and Pharmacology, 1995, 35, 501-505.	2.3	16
290	Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin. Cancer Chemotherapy and Pharmacology, 1995, 35, 257-261.	2.3	28
291	Pharmacological Properties of Oral Idarubicin. Clinical Drug Investigation, 1995, 9, 1-8.	2.2	6
292	Direct evaluation of intracellular accumulation of free and polymer-bound anthracyclines. Cancer Chemotherapy and Pharmacology, 1995, 35, 501-505.	2.3	0
293	Lymphoid Tumors of <i>Xenopus laevis</i> with Different Capacities for Growth in Larvae and Adults. Autoimmunity, 1994, 3, 297-307.	0.6	59
294	Intracellural accretion of free and nanosphere-encapsulated doxorubicin. Bulletin of Experimental Biology and Medicine, 1994, 118, 1106-1109.	0.8	3
295	Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. Biomedical Applications, 1994, 661, 133-141.	1.7	89
296	Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil. British Journal of Cancer, 1994, 69, 868-874.	6.4	16
297	Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance. Cancer Chemotherapy and Pharmacology, 1994, 35, 53-58.	2.3	4
298	Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. European Journal of Cancer, 1994, 30, 89-93.	2.8	128
299	Individual dose adaptation of anticancer drugs. European Journal of Cancer, 1994, 30, 844-851.	2.8	47
300	Clinical Pharmacokinetics of Epirubicin. Clinical Pharmacokinetics, 1994, 26, 428-438.	3.5	62
301	Comparison of 12 multidrug-resistance modulating agents in a model of doxorubicin-resistant rat glioblastoma cells in vitro. , 1994, , 713-719.		0
302	Proposals for concomitant use of several modulators of multidrug resistance in clinics. Anticancer Research, 1994, 14, 2371-3.	1.1	10
303	Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Research, 1994, 54, 6330-3.	0.9	66
304	Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells. Anticancer Research, 1994, 14, 99-103.	1.1	4
305	Differential over-expression ofmdr1 genes in multidrug-resistant rat glioblastoma cell lines selected with doxorubicin or vincristine. International Journal of Cancer, 1993, 55, 115-121.	5.1	17
306	New drug design and development in cancer: present status and future perspectives. Cancer Chemotherapy and Pharmacology, 1993, 32, 83-84.	2.3	1

#	Article	IF	CITATIONS
307	Use of pharmacokinetic-pharmacodynamic relationships in the development of new anthracyclines. Cancer Chemotherapy and Pharmacology, 1993, 32, 99-102.	2.3	9
308	Doxorubicin-induced lipid peroxidation and glutathione peroxidase activity in tumor cell lines selected for resistance to doxorubicin. FEBS Journal, 1993, 211, 141-146.	0.2	47
309	Expression of P-glycoprotein and anionic glutathione S-transferase genes in non-hodgkin's lymphoma. Leukemia Research, 1993, 17, 149-156.	0.8	49
310	Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines. Journal of Cancer Research and Clinical Oncology, 1993, 119, 527-532.	2.5	6
311	Doxorubicin-induced oxygen free radical formation in sensitive and doxorubicin-resistant variants of rat glioblastoma cell lines. FEBS Letters, 1993, 322, 295-298.	2.8	15
312	Doxorubicin-induced oxygen free radical formation in sensitive and doxorubicin-resistant variants of rat glioblastoma cell lines. FEBS Letters, 1993, 326, 302-305.	2.8	15
313	Aspects of the cellular pharmacology of N-I-leucyldoxorubicin in human tumor cell lines. Biochemical Pharmacology, 1993, 45, 1929-1931.	4.4	8
314	Clinical Pharmacokinetics of Idarubicin. Clinical Pharmacokinetics, 1993, 24, 275-288.	3.5	44
315	Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells. European Journal of Cancer, 1993, 29, 1377-1383.	2.8	30
316	Epirubicin. Drugs, 1993, 45, 20-30.	10.9	58
317	Expression of MDR1/P glycoprotein in human sarcomas. British Journal of Cancer, 1993, 68, 1221-1226.	6.4	37
318	Diffusion of a particular 4.1(â^') hereditary elliptocytosis allele in the French northern Alps. Journal of Biosocial Science, 1993, 25, 239-247.	1.2	6
319	Pharmacokinetics and metabolism of anthracyclines. Cancer Surveys, 1993, 17, 219-52.	1.5	59
320	An abnormal concentration of cases of Rendu-Osler disease in the Valserine valley of the French Jura: a genealogical and demographic study. Annals of Human Biology, 1992, 19, 233-247.	1.0	52
321	Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities. Clinical Pharmacology and Therapeutics, 1992, 51, 249-259.	4.7	17
322	P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines. British Journal of Cancer, 1992, 65, 538-544.	6.4	44
323	Original article: Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma. Annals of Oncology, 1992, 3, 651-656.	1.2	16
324	Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans Journal of Clinical Oncology, 1992, 10, 1183-1190.	1.6	11

#	Article	IF	CITATIONS
325	In Vitro Growth of Thymic Tumor Cell Lines from Xenopus. Autoimmunity, 1992, 2, 295-307.	0.6	42
326	Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemotherapy and Pharmacology, 1992, 29, 391-395.	2.3	59
327	Drug resistance in oncology: from concepts to applications. Journal of Cancer Research and Clinical Oncology, 1992, 119, 76-86.	2.5	14
328	Measurement of doxorubicin-induced lipid peroxidation under the conditions that determine cytotoxicity in cultured tumor cells. Analytical Biochemistry, 1992, 201, 326-330.	2.4	21
329	Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hematological Oncology, 1992, 10, 111-116.	1.7	51
330	Shifts in interleukin-4 and interferon-Î ³ production by T cells of patients with elevated serum IgE levels and the modulatory effects of these lymphokines on spontaneous IgE synthesis. Journal of Allergy and Clinical Immunology, 1991, 87, 58-69.	2.9	229
331	Limited sampling models for doxorubicin pharmacokinetics Journal of Clinical Oncology, 1991, 9, 871-876.	1.6	44
332	A Xenopus laevis creatine kinase isozyme (CK-III/III) expressed preferentially in larval striated muscle: cDNA sequence, developmental expression and subcellular immunolocalization. Genetical Research, 1991, 58, 35-40.	0.9	8
333	Differential expression of creatine kinase isozymes during development of Xenopus laevis: An unusual heterodimeric isozyme appears at metamorphosis. Differentiation, 1991, 46, 23-34.	1.9	9
334	A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. Cancer Chemotherapy and Pharmacology, 1991, 29, 75-79.	2.3	21
335	Development of Mechanisms of Protection Against Oxidative Stress in Doxorubicin-Resistant Rat Tumoral Cells in Culture. Free Radical Research Communications, 1990, 11, 137-144.	1.8	11
336	Cellular pharmacology of 4'-iodo-4'-deoxydoxorubicin. British Journal of Cancer, 1990, 61, 543-547.	6.4	10
337	Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug. Cancer Chemotherapy and Pharmacology, 1990, 27, 147-150.	2.3	19
338	Influence of trimetazidine on deleterious effect of oxygen radical species in post-ischemic acute renal failure in the rat. Cardiovascular Drugs and Therapy, 1990, 4, 816-817.	2.6	7
339	Fraser syndrome with renal agenesis in two consanguineous Turkish families. American Journal of Medical Genetics Part A, 1990, 36, 477-479.	2.4	24
340	Antilipoperoxydant Effect of Trimetazidine in Post Ischaemic Acute Renal Failure in the Rat. Advances in Experimental Medicine and Biology, 1990, 264, 383-388.	1.6	2
341	Developmental expression of the creatine kinase isozyme system of <i>Xenopus:</i> maternally derived CK-IV isoform persists far beyond the degradation of its maternal mRNA and into the zygotic expression period. Development (Cambridge), 1990, 108, 507-514.	2.5	11
342	Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients. Leukemia, 1990, 4, 227-9.	7.2	16

#	Article	IF	CITATIONS
343	Ageâ€related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. American Journal of Medical Genetics Part A, 1989, 32, 291-297.	2.4	526
344	Assessment of the experimental model of transplanted C6 glioblastoma in wistar rats. Journal of Neuro-Oncology, 1989, 7, 299-304.	2.9	65
345	Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients. European Journal of Cancer & Clinical Oncology, 1989, 25, 505-511.	0.7	19
346	DUCHENNE MUSCULAR DYSTROPHY: NEONATAL SCREENING AND PRENATAL DIAGNOSIS. Lancet, The, 1989, 333, 669.	13.7	19
347	Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells. Biochemical Pharmacology, 1989, 38, 167-172.	4.4	51
348	Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochemical Pharmacology, 1989, 38, 4069-4074.	4.4	71
349	The reversal of doxorubicin resistance by verapamil is not due to an effect on calcium channels. International Journal of Cancer, 1988, 41, 283-286.	5.1	33
350	Purification and characterization of cytoplasmic creatine kinase isozymes ofXenopus laevis. Biochemical Genetics, 1988, 26, 543-555.	1.7	8
351	Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes. Biochemical Pharmacology, 1988, 37, 3877-3887.	4.4	68
352	Alteration of ganglioside composition and metabolism in doxorubicin-resistant rat tumoral cells. Lipids and Lipid Metabolism, 1988, 963, 553-557.	2.6	3
353	Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients. European Journal of Cancer & Clinical Oncology, 1988, 24, 1289-1294.	0.7	17
354	Continuous Infusion or Intravenous Bolus: What Is the Rationale for Doxorubicin Administration?. Cancer Drug Delivery, 1987, 4, 191-199.	0.7	21
355	Free fatty acid uptake is increased in doxorubicin-resistant glioblastoma cells. Biochimica Et Biophysica Acta - Biomembranes, 1987, 902, 149-153.	2.6	8
356	Pharmacokinetics of doxorubicin in sarcoma patients. European Journal of Clinical Pharmacology, 1987, 31, 695-699.	1.9	29
357	Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated prefused rat liver. Cancer Chemotherapy and Pharmacology, 1987, 19, 240-5.	2.3	43
358	Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients. Leukemia Research, 1987, 11, 961-964.	0.8	15
359	Fluorescence anisotropy of kidney lipids and membranes of a hibernating mammal. Cryobiology, 1986, 23, 177-183.	0.7	8
360	Evaluation of Drug Therapy and Teratogenic Risk in a Rhone-Alpes District Population of Pregnant Epileptic Women. European Neurology, 1986, 25, 436-443.	1.4	32

#	Article	IF	CITATIONS
361	Cellular Pharmacology of Doxorubicin in Sensitive and Resistant Rat Glioblastoma Cells in Culture. Oncology, 1986, 43, 60-66.	1.9	22
362	Metabolism of doxorubicin and epirubicin in adult human hepatocytes in culture. Pharmacological Research Communications, 1986, 18, 343-347.	0.2	12
363	Hepatic metabolism of doxorubicin in mice and rats. European Journal of Drug Metabolism and Pharmacokinetics, 1986, 11, 101-105.	1.6	8
364	Fatty Acid Composition and Metabolism of Tumor Cells Rendered Resistant to the Anticancer Drug Doxorubicin. , 1986, , 473-478.		1
365	Fatty acid composition transport and metabolism in doxorubicin-sensitive and-resistant rat glioblastoma cells. Cancer Research, 1986, 46, 3258-61.	0.9	27
366	Fluorescence anisotropy of cell membranes of doxorubicin-sensitive and -resistant rodent tumoral cells. Cancer Research, 1986, 46, 5602-5.	0.9	24
367	Incorporation and turnover of phospholipid precursors in normal and tumoral glial cells in culture. International Journal of Biochemistry & Cell Biology, 1985, 17, 611-617.	0.5	6
368	Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients. European Journal of Cancer & Clinical Oncology, 1985, 21, 1307-1313.	0.7	19
369	Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treatment Reports, 1985, 69, 633-40.	0.5	56
370	Tentative dose-monitoring of doxorubicin in lymphoma patients. Medical Oncology and Tumor Pharmacotherapy, 1985, 2, 255-259.	1.1	6
371	Cellular Pharmacokinetics of Doxorubicin in Cultured Mouse Sarcoma Cells Originating from Autochthonous Tumors. Oncology, 1984, 41, 55-60.	1.9	16
372	Fluorescence polarization study of lipids and membranes prepared from brain hemispheres of a hibernating mammal. Biochemical and Biophysical Research Communications, 1984, 119, 396-400.	2.1	15
373	Early-phase pharmacokinetics of doxorubicin in non-hodgkin lymphoma patients. Cancer Chemotherapy and Pharmacology, 1983, 10, 115-119.	2.3	20
374	Incorporation and metabolism of exogenous fatty acids by cultured normal and tumoral glial cells. Lipids and Lipid Metabolism, 1983, 752, 383-395.	2.6	43
375	Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Research, 1983, 43, 4467-9.	0.9	62
376	Pharmacokinetics of adriamycin in patients with breast cancer: Correlation between pharmacokinetic parameters and clinical short-term response. European Journal of Cancer & Clinical Oncology, 1982, 18, 739-745.	0.7	85
377	Changes in lipid composition of the brain cellular membranes of an hibernating mammal during its circannual rhythm. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1982, 71, 409-416.	0.2	3
378	Metabolism of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells. Cancer Chemotherapy and Pharmacology, 1982, 9, 45-48.	2.3	11

#	Article	IF	CITATIONS
379	Rectocolic familial polyposis; a study of 32 cases. World Journal of Surgery, 1981, 5, 617-625.	1.6	3
380	Sanfilippo A syndrome (Mucopolysaccharidosis III A): a neurochemical study. Italian Journal of Neurological Sciences, 1981, 2, 119-127.	0.1	3
381	Phospholipid acyl group composition in normal and tumoral nerve cells in culture. Lipids, 1981, 16, 293-297.	1.7	29
382	Effects of prior therapy on plasma levels of adriamycin during subsequent therapy. Journal of Medicine, 1981, 12, 183-93.	0.1	10
383	Uptake of l-Glutamate and Taurine in Neuroblastoma Cells with Altered Fatty Acid Composition of Membrane Phospholipids. Journal of Neurochemistry, 1980, 34, 1678-1681.	3.9	48
384	Extraction of Anthracyclines from Biological Fluids for HPLC Evaluation. Journal of Liquid Chromatography and Related Technologies, 1980, 3, 1561-1572.	1.0	94
385	Glycolipids and Cell Differentiation. Advances in Experimental Medicine and Biology, 1980, 125, 159-166.	1.6	16
386	Neuronal and Glial Cell Cultures, a Tool for Investigation of Ganglioside Function. Advances in Experimental Medicine and Biology, 1980, 125, 515-531.	1.6	40
387	Dynamics of Phospholipids in Cultured Cells of Neural Origin. Biochemical Society Transactions, 1979, 7, 341-345.	3.4	3
388	Membrane lipids in bromodeoxyuridine-differentiated astroglial cells in culture. Lipids, 1979, 14, 852-859.	1.7	14
389	UTILIZATION OF POLYUNSATURATED FATTY ACID SUPPLEMENTS BY CULTURED NEUROBLASTOMA CELLS. Journal of Neurochemistry, 1978, 30, 543-548.	3.9	54
390	SYSTEMATIC NEONATAL SCREENING FOR DUCHENNE MUSCULAR DYSTROPHY. Lancet, The, 1978, 312, 1100.	13.7	20
391	Polar head groups manipulation of phospholipids in cultured neuroblastoma cells. Life Sciences, 1978, 22, 211-215.	4.3	13
392	Confirmation of the assignment of the human <i>SOD_S </i> gene to chromosome 21q22. Cytogenetic and Genome Research, 1978, 22, 521-523.	1.1	25
393	IS VARICELLA VIRUS TERATOGENIC?. Lancet, The, 1977, 309, 362.	13.7	1
394	Essential fatty acid metabolism in cultured astroblasts. Biochimie, 1977, 59, 417-423.	2.6	38
395	Thin-layer chromatography of gangliosides. Journal of Chromatography A, 1977, 137, 481-484.	3.7	25
396	Gangliosides of Active and Inactive Neuroblastoma Clones. Differentiation, 1977, 8, 31-37.	1.9	27

#	Article	IF	CITATIONS
397	Glycosphingolipids from cultured astroblasts. Journal of Lipid Research, 1977, 18, 517-522.	4.2	29
398	Glycosphingolipids from cultured astroblasts. Journal of Lipid Research, 1977, 18, 517-22.	4.2	24
399	NEUTRAL LIPIDS AND PHOSPHOLIPIDS FROM CULTURED ASTROBLASTS. Journal of Neurochemistry, 1976, 26, 771-777.	3.9	16
400	NEUTRAL LIPIDS AND PHOSPHOLIPIDS FROM CULTURED ASTROBLASTS. Journal of Neurochemistry, 1976, 26, 771-777.	3.9	0
401	Changes in Sugar* Composition of Membrane-Bound Glycoproteins during Postnatal Development of Rat Cerebellum. Biochemical Society Transactions, 1975, 3, 694-696.	3.4	3
402	Changes of Ganglioside Pattern during Postnatal Development of Rat Cerebellum. Biochemical Society Transactions, 1975, 3, 696-698.	3.4	10
403	Quantitation of neutral glycolipids by thin-layer chromatography on precoated plates. Journal of Chromatography A, 1975, 110, 393-397.	3.7	27
404	Gangliosides of glial cells: A comparative study of normal astroblasts in tissue culture and glial cells isolated on sucrose-ficoll gradients. FEBS Letters, 1975, 50, 144-146.	2.8	63
405	Reversal Agents of Multidrug Resistance Mediated by Multidrug Resistance-Associated Proteins (MRPs). , 0, , 261-288.		2